Integra rises after resolving FDA warning letter
This article was originally published in Clinica
Executive Summary
Integra LifeSciences’ share price closed up 3% at $39.78 yesterday, after the company resolved a US FDA warning letter relating to problems at its Plainsboro, New Jersey manufacturing facility. The letter, dated December 2011, involved “quality systems and compliance issues.”